Contact Mary Bordoni, Director, Membership & Development, for information about joining the Coalition.
In a blog titled "Two Recent Scientific Advances Underscore an Encouraging Future for Precision Medicine at FDA," the agency's Center for Drug Evaluation and Research Director Janet Woodcock, M.D., welcomes new developments in personalized medicine, which she notes is a powerful tool for developing drugs that benefit patients with particular biological characteristics. The agency, she said, believes it is important to make personalized medicines available to patients, and is "actively pursuing more advances" in the field.
» FDA Voice: Two Recent Scientific Advances Underscore an Encouraging Future for Precision Medicine at FDA
In pursuit of progress for personalized medicine, PMC recently weighed in on U.S. President Donald Trump's proposal to cut research funding for the National Institutes of Health, a new proposal that would revise the framework for the regulation of laboratory-developed tests (LDTs), and Rep. Eric Swalwell's (D-CA)'s "Access to Precision Medicine Advancement Act." The advocacy efforts are designed to support a friendlier policy landscape for the field.
» Public Policy